KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Cost of Revenue (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Cost of Revenue data on record, last reported at -$4.8 million in Q4 2025.

  • For Q4 2025, Cost of Revenue fell 144.28% year-over-year to -$4.8 million; the TTM value through Dec 2025 reached $5.7 million, down 67.9%, while the annual FY2025 figure was $5.7 million, 67.9% down from the prior year.
  • Cost of Revenue reached -$4.8 million in Q4 2025 per AQST's latest filing, down from $4.5 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $10.8 million in Q4 2024 and bottomed at -$14.1 million in Q4 2022.
  • Average Cost of Revenue over 5 years is $2.7 million, with a median of $4.4 million recorded in 2021.
  • Peak YoY movement for Cost of Revenue: crashed 518.33% in 2022, then soared 235.86% in 2025.
  • A 5-year view of Cost of Revenue shows it stood at $3.4 million in 2021, then plummeted by 518.33% to -$14.1 million in 2022, then skyrocketed by 138.93% to $5.5 million in 2023, then surged by 96.39% to $10.8 million in 2024, then plummeted by 144.28% to -$4.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were -$4.8 million in Q4 2025, $4.5 million in Q3 2025, and $4.6 million in Q2 2025.